Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 23;22(1):242.
doi: 10.1186/s12936-023-04657-5.

Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report

Corinne S Merle  1 ; RTSS-SMC working group
Collaborators, Affiliations

Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report

Corinne S Merle et al. Malar J. .

Abstract

A workshop on implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission, was held as a hybrid meeting in Dakar, Senegal, and online, 23-25 January 2023. Delegates from Expanded Programmes on Immunization (EPI) and National Malaria Control Programmes (NMCPs) from 13 African countries, and representatives from key stakeholders participated. RTS,S is the first malaria vaccine to be recommended by the World Health Organization (WHO). The recommendation followed pilot implementation of the vaccine in Ghana, Kenya and Malawi, which showed that introduction of the vaccine was highly effective at scale, and was associated with a 30% reduction in hospital admissions with severe malaria in age groups eligible to have received the vaccine and no evidence of the safety signals that had been observed in the phase 3 trial. Clinical trials in Mali and Burkina Faso, showed that in children receiving Seasonal Malaria Chemoprevention (SMC), providing the vaccine just prior to high transmission seasons, matching the period of highest efficacy to the peak transmission season, resulted in substantial reduction in the incidence of clinical malaria and of severe malaria. While SMC has been successfully scaled-up despite the challenges of delivery, there is no established platform for seasonal vaccine delivery and no real-world experience. The objectives of this workshop were, therefore, to share experiences from countries that have introduced the RTS,S vaccine in routine child vaccination programmes, with SMC-implementing countries as they consider malaria vaccine introduction, and to explore implementation strategies in countries with seasonal transmission and where EPI coverage may be low especially in the second year of life. Practical implementation challenges, lessons learned for vaccine introduction, and research questions, towards facilitating the introduction of the RTS,S (and other malaria vaccines) in countries with seasonal malaria transmission were discussed.

Keywords: EPI; Implementation research; Low- and middle-income countries (LMIC); Malaria transmission; RTS,S vaccine; Seasonal malaria chemoprevention (SMC).

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interest.

Figures

Fig. 1
Fig. 1
Areas which implement seasonal malaria chemoprevention (SMC), courtesy of OPT-SMC project
Fig. 2
Fig. 2
EPI vaccine schedules in RTS,S pilot countries Ghana, Kenya and Malawi (with thanks to WHO)
Fig. 3
Fig. 3
Recommendations from Post-introduction Evaluation (PIE) conducted across RTS,S pilot countries (Ghana, Malaria and Kenya)
See this image and copyright information in PMC

References

    1. Weekly epidemiological record. Malaria vaccine: WHO position paper—March 2022. 2022.
    1. Praet N, Asante KP, Bozonnat MC, Akité EJ, Ansah PO, Baril L, et al. Assessing the safety, impact and effectiveness of RTS, S/AS01E malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up. Malar J. 2022;21:132. doi: 10.1186/s12936-022-04144-3. - DOI - PMC - PubMed
    1. Datoo MS, Natama MH, Somé A, Traoré O, Rouamba T, Bellamy D, et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet. 2021;397:1809–1818. doi: 10.1016/S0140-6736(21)00943-0. - DOI - PMC - PubMed
    1. Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga RS, Diarra M, et al. Seasonal malaria vaccination with or without seasonal malaria chemoprevention. N Engl J Med. 2021;385:1005–1017. doi: 10.1056/NEJMoa2026330. - DOI - PubMed
    1. WHO. World malaria report 2022 [Internet]. Geneva, World Health Organization, 2022. https://www.who.int/teams/global-malaria-programme. Accessed 14 Aug 2023.

Publication types

Substances

LinkOut - more resources